10,889 Shares in Integra LifeSciences Holdings Co. (NASDAQ:IART) Acquired by Dynamic Technology Lab Private Ltd

Dynamic Technology Lab Private Ltd bought a new stake in Integra LifeSciences Holdings Co. (NASDAQ:IART) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 10,889 shares of the life sciences company’s stock, valued at approximately $198,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Price T Rowe Associates Inc. MD increased its position in Integra LifeSciences by 6.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 35,421 shares of the life sciences company’s stock worth $1,256,000 after purchasing an additional 2,114 shares during the last quarter. Jane Street Group LLC raised its stake in shares of Integra LifeSciences by 181.1% in the 1st quarter. Jane Street Group LLC now owns 124,887 shares of the life sciences company’s stock valued at $4,427,000 after acquiring an additional 80,463 shares during the period. CWM LLC lifted its holdings in shares of Integra LifeSciences by 50.8% in the 2nd quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock worth $37,000 after acquiring an additional 425 shares during the last quarter. Olstein Capital Management L.P. boosted its position in shares of Integra LifeSciences by 13.0% during the 2nd quarter. Olstein Capital Management L.P. now owns 113,000 shares of the life sciences company’s stock worth $3,293,000 after purchasing an additional 13,000 shares during the period. Finally, Cardinal Capital Management raised its position in Integra LifeSciences by 9.5% in the second quarter. Cardinal Capital Management now owns 34,034 shares of the life sciences company’s stock valued at $992,000 after purchasing an additional 2,965 shares during the period. 84.78% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. BTIG Research upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating in a research report on Monday, October 7th. Truist Financial dropped their target price on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating for the company in a research report on Monday, October 14th. Morgan Stanley started coverage on shares of Integra LifeSciences in a research report on Monday. They set an “underweight” rating and a $20.00 price target on the stock. Bank of America cut their target price on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating on the stock in a research note on Monday, October 7th. Finally, Citigroup raised their price target on shares of Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a research report on Tuesday, November 5th. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $23.00.

Integra LifeSciences Stock Performance

Shares of IART stock opened at $24.58 on Tuesday. The company has a market cap of $1.90 billion, a P/E ratio of -273.11, a PEG ratio of 0.84 and a beta of 1.08. The firm has a fifty day moving average price of $20.77 and a 200 day moving average price of $23.96. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. Integra LifeSciences Holdings Co. has a 12 month low of $16.81 and a 12 month high of $45.42.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Monday, November 4th. The life sciences company reported $0.41 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.02. The business had revenue of $380.80 million for the quarter, compared to the consensus estimate of $375.81 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The business’s revenue for the quarter was down .4% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.76 EPS. Sell-side analysts predict that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.